|
|
||||||||
Clinical Chemistry, Vol 37, 1423-1429, Copyright © 1991 by American Association for Clinical Chemistry
MA Carbonneau, E Peuchant, D Sess, P Canioni and M Clerc
Laboratoire de Biochimie Medicale A., Universite de Bordeaux II, France.
Assay of free and total malondialdehyde (MDA) in human serum and plasma from healthy subjects and from patients with high risk of lipoperoxidation was performed as follows: (a) acidic (HClO4, pH 1, at 20 degrees C) or basic (NaOH, pH 13, at 60 degrees C) treatments for 30 min; (b) reaction of the protein-free extract (obtained by acid precipitation) with thiobarbituric acid (TBA); (c) HPLC separation on C18 columns with an eluting solution of methanol/phosphate buffer, 10 mmol/L, pH 5.8 (40/60, by vol), at a flow rate of 1.5 mL/min. Free MDA averaged 0.042 (SEM 0.008) and 0.043 (SEM 0.007) mumol/L, respectively, in serum and plasma from healthy subjects. Free (+/- SEM) MDA increased significantly in the plasma from cancer patients (0.270 +/- 0.047 mumol/L) and from hemodialyzed patients (0.214 +/- 0.035 mumol/L). In serum of hemodialyzed patients, analyses for total MDA were unsuitable because of interfering peaks. MDA bound to NH2 groups constituted 83.2% and 83.5% of total MDA in serum and plasma of healthy subjects, respectively, and only 58% in plasma of hemodialyzed patients.
The following articles in journals at HighWire Press have cited this article:
![]() |
M. F. Walter, R. F. Jacob, R. E. Bjork, B. Jeffers, J. Buch, Y. Mizuno, R. P. Mason, and on behalf of the PREVENT Investigators Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease: The PREVENT Study J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1196 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Keller, F. A. Schmitt, S. W. Scheff, Q. Ding, Q. Chen, D. A. Butterfield, and W. R. Markesbery Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology, April 12, 2005; 64(7): 1152 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Walter, R. F. Jacob, B. Jeffers, M. M. Ghadanfar, G. M. Preston, J. Buch, and R. P. Mason Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1996 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bozzini, D. Girelli, E. Tinazzi, O. Olivieri, C. Stranieri, A. Bassi, E. Trabetti, G. Faccini, P. F. Pignatti, and R. Corrocher Biochemical and Genetic Markers of Iron Status and the Risk of Coronary Artery Disease: An Angiography-based Study Clin. Chem., April 1, 2002; 48(4): 622 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Badcock, G. D. Zoanetti, and E. S. Martin Nonchromatographic Assay for Malondialdehyde–Thiobarbituric Acid Adduct with HPLC Equivalence Clin. Chem., September 1, 1997; 43(9): 1655 - 1657. [Full Text] |
||||
![]() |
F. Nielsen, B. B. Mikkelsen, J. B. Nielsen, H. R. Andersen, and P. Grandjean Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors Clin. Chem., July 1, 1997; 43(7): 1209 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Massafra, G. Buonocore, D. Gioia, I. Sargentini, and G. Farina Effects of Estradiol and Medroxyprogesterone-Acetate Treatment on Erythrocyte Antioxidant Enzyme Activities and Malondialdehyde Plasma Levels in Amenorrhoic Women J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 173 - 175. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |